Eton Pharmaceuticals Adds Orphan Drug IMPAVIDO® to Rare Disease Portfolio via U.S. Commercialization Deal
ETON has more than doubled off its 52-week low of $13.085.
Summary
Eton Pharmaceuticals has secured U.S. commercialization rights for IMPAVIDO® (miltefosine), an orphan drug indicated for the treatment of leishmaniasis, through a supply and distribution agreement with an affiliate of Knight Therapeutics. This move expands Eton's rare disease portfolio, aligning with its stated strategy to grow through product launches and acquisitions. The company recently reported strong Q1 2026 results, with a 73% increase in product sales driven by its expanded portfolio, and this agreement represents another step in that growth trajectory. While specific financial terms were not disclosed, adding a commercially available, life-saving medication reinforces Eton's focus on specialized patient populations and could contribute to future revenue streams. Traders will monitor the financial impact of this agreement in upcoming earnings reports.
At the time of this announcement, ETON was trading at $32.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $900.9M. The 52-week trading range was $13.09 to $33.41. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.